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Abstract: To investigate the biological profile of the previtamin form 
of vitamin D, we have synthesized new analogues of 19-nor-1α,25-
dihydroxyprevitamin D3 bearing a 2-hydroxyethylidene moiety at the 
A-ring. The target compounds were prepared by convergent 
synthesis employing the Sonogashira coupling between an A-ring 
enyne synthon and a CD-ring/side chain vinyl triflate. We have 
demonstrated the versatility of shikimic acid as starting material for 
the synthesis of the A-ring precursors. The binding affinity to Vitamin 
D Receptor (VDR) and Vitamin D Binding Protein (DBP), and MCF-7 
cell antiproliferative activity have been evaluated. 
Introduction 
Over the last three decades, more than 3,000 analogues of 
vitamin D3 (1, Figure 1) have been synthesized because of the 
therapeutic applications of 1α,25-dihydroxyvitamin D3 (2), the 
hormonally active form of vitamin D3. In addition to its classical 
role in the regulation of calcium homeostasis and bone 
metabolism,[1] this hormone and its derivatives are associated 
with the inhibition of cell growth, the stimulation of cell 
differentiation, and the regulation of the immune system, among 
other activities.[2] Several laboratories have worked on the 
development of clinically useful vitamin D3 drugs for a diverse 
set of disease indications. As a result, more than nine analogues 
are currently on the market in the United States, Japan, or 
Europe for clinical uses, with many more in development.[3] 
The crystal structures of vitamin D3 derivatives with different 
biological activities in complex with Vitamin D receptor (VDR) do 
not exhibit significant changes, suggesting the adaptability of the 
vitamin D3 ligand along with the potential flexibility of the 
protein.[4] Several modifications in the vitamin D3 skeleton have 
been reported.[5] 19-nor-Vitamin D3 analogues (3), in which the 
exomethylene group at C-19 was removed, have received much 
attention as compounds characterized by dissociation of cell 
differentiation and calcemic activities.[6] In this context, 
introduction of substituents at the C-2 position of the A-ring 
causes changes in the biological profile compared with the 
parent 19-nor-vitamin D3.[7] Among them, the group (2E)-
hydroxyethylidene have been described to give place to stronger 
VDR affinity and ligand-dependent transcriptional activity 
compared with the natural 1α,25-dihydroxyvitamin D3.[8] It was 
found that the incorporation of the (2E)-hydroxyethylidene 
substituent in 19-nor-vitamin D derivatives with a 22,24-diene, 
22-oxa, or 16-ene-22-thia-26,27-dimethyl modifications showed 
higher potency in the transcriptional assay.[9] Furthermore, 
analogues bearing 20S-configuration presented much higher 
ability to induce osteoclast formation and inhibition of the 
expression of the dendritic cells maturation marker CD86 than 
their corresponding 20R-counterpart.[10] 
  
Figure 1. Chemical structures of vitamin D3 (1), 1α,25-dihydroxyvitamin D3 (2), 
and 19-nor analogues (3). 
The hormone 1α,25-dihydroxyvitamin D3 exists in thermal 
equilibrium (5-10%) with 1α,25-dihydroxyprevitamin D3.[11] Most 
of the developed analogues are focused in the vitamin D form 
due to the spontaneous isomerization of 1α,25-(OH)2-pre-D3 (4) 
to the more stable 1α,25-(OH)2-D3 (2) via [1,7]-sigmatropic 
hydrogen shift (Scheme 1). However, scarce examples of 
previtamin D analogues are described in the literature. These 
include the four A-ring diastereoisomers of 19-nor-1α,25-(OH)2-
pre-D3,[12] a 9,19-methano-bridged analogue of 1α,25-(OH)2-
D3,[13] and a series of 2-substituted derivatives of 14-epi-
previtamin D3,[14] in which the 14-epi-1α,25-(OH)2-pre-D3 form 
was major and dominant to 14-epi-1α,25-(OH)2-D3. In our 
laboratory, we have synthesized conformationally locked 
previtamin D3 derivatives with a 2-hydroxy, 2β-(3’-
hydroxypropoxy), or a 2β,3β-epoxy group.[15] To the best of our 
knowledge, the unique reported previtamin D analogue with 
activities equivalent to 1α,25-(OH)2-D3 is characterized by the 
presence of a trans-fused decalin CD-ring system.[16] This 
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analogue, developed by Bouillon and coworkers, interacts as 
efficiently as the natural hormone with the VDR and uses the 
same contact points within the receptor as 1α,25-(OH)2-D3. 
Challenges remain in the design of new analogs and the 
evaluation of its biological actions in order to investigate 
structure-activity relationships. 
 
Scheme 1. Equilibrium of 1α,25-dihydroxyvitamin D3 (2) and 1α,25-
dihydroxyprevitamin D3 (4). 
On the basis of the above mentioned considerations and our 
ongoing interest in the preparation and biological evaluation of 
vitamin D3 derivatives,[17] herein, we report the synthesis and 
biological activities of a series of 19-nor-previtamin D3 analogues 
(5, 6, and 7, Figure 2) that possess the hydroxyethylidene 
function in different positions of the A-ring. The synthetic 
strategy involves the coupling of a dienyne precursor of the A-
ring with an enol triflate of the CD-ring/side chain fragment. 
 
Figure 2. Targeted hydroxyalkyliden-19-nor-previtamin D3 analogues. 
Results and Discussion 
Chemistry. The A-ring precursors were synthesized starting 
from commercially available shikimic acid (8, Scheme 2). The 
selective protection of the 3- and 5-hydroxy groups and the 
reduction of the ester to aldehyde, as previously described,[15a] 
generated compound 9. Transformation of the latter into the 
enyne 10 was accomplished with a 56% yield by reaction with 
trimethylsilyldiazomethane. For the introduction of the 
hydroxyethylidene function, the free OH group in C-4 was 
oxidized with Dess-Martin periodinane reagent, affording ketone 
11 as a single product in the TLC. This compound showed to be 
unstable to standard purification by column chromatography, 
being isolated with a 78% yield (neutral silica gel). 
 
Scheme 2. Reagents and conditions: a) DMP, CH2Cl2, rt, overnight, 78%; b) 
(EtO)2P(O)CH2CN, nBuLi, THF, –40 °C, 1 h, 82%; c) DIBAL-H, toluene, –78 °C, 
1 h, 65%; d) NaBH4, EtOH, 0 °C, 45 min, 78%; e) TBDMSCl, imidazole, 
CH2Cl2, 0 °C to rt, 1 h, 97%. 
Cyanomethylation of 11 with the ylide generated from 
diethyl(cyanomethyl)phosphonate and n-butyllithium gave 
derivative 12 as an approximately 60:40 mixture of E and Z 
isomers and 82% yield. Both isomers were reduced with 
diisobutylaluminium hydride followed by sodium borohydride to 
afford 2-(2-hydroxyethylidene) derivative 14. Protection of the 
free hydroxy group of 14 with tert-butyldimethylsilyl chloride 
yielded the desired A-ring synthons 15a (E isomer) and 15b (Z 
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isomer), which could be separated by semipreparative HPLC in 
excellent yield. Configuration of the ethylidene unit was 
unambiguously determined by 2D NOESY spectroscopy 
experiments (Figure 3). In 15a, a correlation cross peak was 
observed between allylic proton H-3 and vinyl proton H-1’. In 
addition, NOE was detected between H-5 and H-2’. From these 
results, the stereochemistry of the C-2 substituent of 15a were 
determined to be E. On the other hand, derivative 15b showed a 
cross peak between H-3 and H-2’, which confirmed a Z 
configuration. A weak NOE connectivity between H-5 and H-1’ 
corroborated the assigned stereochemistry for 15b. 
 
Figure 3. NOE connectivities for 15a and 15b. 
In the scale-up preparation of compound 10, migration of the O-
silyl group was occasionally observed, giving a mixture of 3,5- 
and 4,5-disilyl ethers. This migration occurs typically under basic 
conditions and proceeds intramolecularly through a 
pentacoordinate silicon intermediate.[18] Therefore, we postulate 
that, since the nBuLi used in the transformation of 9 to 10 also 
contains LiOH to a greater or lesser extent, depending on the 
nBuLi batch, different ratio of regioisomers from 99:1 to 1:1 
(10:16) was observed. Both derivatives could be isolated by 
semipreparative HPLC chromatography for characterization. 
 
Scheme 3. Reagents and conditions: a) MnO2, CH2Cl2, rt, 16 h, 86%; b) 
(EtO)2P(O)CH2CN, nBuLi, THF, –40 °C, 2.5 h, 89%; c) DIBAL-H, toluene,  
–78 °C, 1 h, 85%; d) NaBH4, EtOH, 0 °C, 45 min, 65%. 
For a practical separation of the unwanted isomer 16, a selective 
oxidation of the allylic alcohol in C-3 was performed with 
manganese dioxide to provide the ketone 17, which could be 
separated from the alcohol 10 via standard column 
chromatography. With the compound 17 in hand, we explored 
the synthesis of the A-ring precursor having a 2-
hydroxyethylidene function attached to the allylic position 
(Scheme 3). Thus, the Wittig-Horner reaction of compound 17 
with diethyl(cyanomethyl)phosphonate produced selectively 18 
as the only isomer. 
The stereochemistry of the 2-hydroxyethylidene moiety of 18 
was determined by analysis of 2D NOESY spectrum. NOE was 
observed between H-1’ and H-4, while a correlation cross peak 
was detected between H-1’ and the tert-butyl of the TBDMS 
group (Figure 4), so this isomer must have the E configuration. 
Next, derivative 18 was treated with DIBAL-H, and the resulting 
aldehyde 19 was transformed into the alcohol 20 by treatment 
with NaBH4. 
 
Figure 4. NOE connectivities for 18 and 28. 
We also explored an alternative pathway to the C-3 
functionalized A-ring precursor from shikimic acid using our 
reported protocol[19] for the one-pot selective protection of the 
trans-1,2-diol. The resulting alcohol 21 was protected as the tert-
butyldimethylsilyl ether, and the ester 22 was transformed into 
the aldehyde 24 by reduction with DIBAL-H and subsequent 
oxidation of the alcohol 23 with Dess-Martin periodinane. 
Treatment of 24 with trimethylsilyldiazomethane provided 25 in 
65% yield. Removal of the silyl protecting group followed by 
oxidation of the hydroxy group gave the corresponding keto 
compound 27. The latter underwent cyanomethylation with 
diethyl(cyanomethyl)phosphonate to afford exclusively 2-
hydroxyethylidene derivative 28. The structure of 28 was proven 
by NOESY experiments (Figure 4). The cross peaks observed 
between H-4/H-5 and the OMe groups of the bisacetal allowed 
the assignment of the OMe groups. The NOE detected between 
H-1’ and the OMe that correlated with H-4 supported the E 
stereochemistry. Transformation of 28 into 31 was carried out 
utilizing the same sequence of reactions as described in 
Scheme 2 for 15. 
The synthesis of previtamin D3 analogues was carried out by 
Sonogashira reaction as outlined in Scheme 5. Coupling of A-
ring synthons 15a, 15b, 20, and 31 with the CD-ring/side chain 
triflate 32[13,20] in the presence of bis(triphenylphosphine)-
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Scheme 4. Reagents and conditions: a) TBDMSCl, imidazole, CH2Cl2, 0 °C to rt, 16 h, 94%; b) DIBAL-H, Et2O, –78 °C, 4 h, 85%; c) DMP, CH2Cl2, rt, 2 h, 94%; d) 
TMSCHN2, nBuLi, THF, –78 °C to rt, 1 h, 65%; e) TBAF, THF, 0 °C to rt, 4 h, 95%; f) from 26, DMP, CH2Cl2, rt, 2 h, 91%; g) (EtO)2P(O)CH2CN, nBuLi, THF,  
–40 °C, 4 h, 80%; h) DIBAL-H, toluene, –78 °C, 1 h, 88%; i) NaBH4, EtOH, 0 °C, 45 min, 75%; j) TBDMSCl, imidazole, CH2Cl2, 0 °C to rt, 1 h, 80%. 
 
Sheme 5. Reagents and conditions: a) (PPh3)2Pd(OAc)2, CuI, Et2NH, DMF, 2 
h, 70% for 33, 90% for 34, 65% for 35, 60% for 36; b) H2, Lindlar catalyst, 
quinoline, hexane, 4 h, 90% for 38, 60% for 37, 90% for 38, 70% for 39, 75% 
for 40; c) TBAF, THF, 0 °C to rt, 4-18 h, 90% for 5, 60% for 6, 85% for 7. 
palladium (II) acetate-copper (I) iodide catalyst yielded the 
dienynes 33, 34, 35, and 36, respectively. Next, catalytic 
hydrogenation with Lindlar catalyst generated derivatives 37, 38, 
39, and 40. Deprotection of the silyloxy groups with TBAF 
afforded the desired previtamins 5, 6, and 7. Several reagents 
were tested for the removal of the bisacetal protecting group in 
40. Among them, trifluoroacetic acid, piridinium p-
toluensulphonate, trimethylsilylbromide and iron (III) chloride. 
However, the previtamin derivative showed to be unstable under 
these conditions, not being possible the access to 7 through this 
route. 
 
Table 1. Biological activities of A-ring modified 2-hydroxyethylidene previtamin 
D3 analogues.[a] 
Compound VDR (%) hDBP (%) MCF-7 (%) 
1α,25-(OH)2-D3 100 100 100 
(2E)-hydroxyethylidene-19-
nor-1α,25-(OH)2-D3 
200[b] --- --- 
5 0 3 4 
7 0 2 0 
[a] Values are expressed as percentages of activity EC50 concentration relative 
to 1α,25-(OH)2-D3 (100%). [b] Reference 8. 
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Biological Evaluation. The biological activity of the newly 
synthesized analogues was tested in vitro, and the results are 
summarized in Table 1 and Figures 5-7. 
 
Figure 5. Affinity of 1α,25-(OH)2-D3 and 2-hydroxyethylidene previtamin D3 
analogues of 1α,25-(OH)2-pre-D3 for pig vitamin D receptor (VDR). Notes: 
1α,25-(OH)2-D3 (●); 5 (∇); 7 (☐). 
For this purpose we evaluated the affinity to pig mucosa cytosol 
VDR and to human Vitamin D Binding Protein (hDBP). Next we 
tested the potency of both compounds to inhibit the proliferation 
of human breast adenocarcinoma MCF-7 cells. Modification by 
the (2E)-hydroxyethylidene group at 19-nor-1α,25-(OH)2-pre-D3 
eliminated the affinity to VDR with respect to (2E)-hydroxy-
ethylidene-19-nor-1α,25-(OH)2-D3, which was about two-fold as 
active as the natural hormone.[8] 
 
Figure 6. Affinity of 1α,25-(OH)2-D3 and 2-hydroxyethylidene previtamin D3 
analogues of 1α,25-(OH)2-pre-D3 for human vitamin D binding protein (hDBP). 
Notes: 1α,25-(OH)2-D3 (●); 5 (∇); 7 (☐). 
These results indicate that 6-s-cis conformer 5 do not have the 
ability as the 6-s-trans isomer to access the VDR binding 
pocket.[21] Compound 7, possessing a (E)-hydroxyethylidene 
group instead of the 1α-hydroxyl group, was also not binding the 
VDR (Figure 5). A similar pattern of relative activities of both 
derivatives was found in the ability to bind the hDBP protein. 
Derivatives 5 and 7 showed a significantly reduced affinity 
compared to 1α,25-(OH)2-D3 (Figure 6). The (2E)-
hydroxyethylidene previtamin D3 analogue 5 was 25 times less 
potent than 1α,25-(OH)2-D3 to inhibit the proliferation of MCF-7 
cells. Derivative 7 with the modification at C-1 demonstrated no 
effects on the MCF-7 cell proliferation (Figure 7). 
 
Figure 7. In vitro antiproliferative effects of 1α,25-(OH)2-D3 and 2-
hydroxyethylidene previtamin D3 analogues of 1α,25-(OH)2-pre-D3 on breast 
cancer MCF-7 cells. Notes: Vehicle (u); 1α,25-(OH)2-D3 (●) ; 5 (∇); 7 (☐). 
Conclusions 
In the present study, we have described the synthesis of new 
locked previtamin D derivatives with a hydroxyethylidene moiety 
at the A-ring. These novel target compounds have been 
synthesized in order to investigate important structure-activity 
features. All analogues were successfully obtained through 
convergent synthesis, starting from shikimic acid, for the 
preparation of the A-ring precursors, and the vinyl triflate of the 
CD-ring/side chain fragment. The hydroxyethylidene group was 
introduced by a Wittig-Horner reaction. NOESY spectroscopy 
experiments were used to assign the stereochemistry of the 
compounds. Their biological activity profiles were assessed in 
terms of affinity for the VDR and DBP, and effects on MCF-7 cell 
proliferation. The C-2 substituted 6-s-cis analogue 5 showed no 
affinity for the VDR but demonstrated very low affinity to hDBP 
and some inhibitory effect on MCF-7 cell proliferation, 
meanwhile analogue with a hydroxyethylidene group at the 1-
position as in compound 7 was unable to bind VDR and devoid 
of in vitro antiproliferative activity on MCF-7 cells. 
    
 
 
 
 
 
Experimental Section 
General 
All reagents were bought from Aldrich at highest commercial quality and 
used without further purification. All non-aqueous reactions were carried 
out under anhydrous conditions in dry, freshly distilled solvents. 
Reactions were monitored by TLC carried out on 0.25 mm Merck silica 
gel plates (60F-254) using UV light as visualizing agent and/or acidic 
aqueous permanganate. Flash chromatography was performed using 
silica gel 60 (230–400 mesh). Melting points were taken on samples in 
open capillary tubes and are uncorrected. IR spectra were recorded as 
thin films on NaCl plates on an Infrared FT spectrophotometer (Agilent or 
Perkin Elmer). NMR spectra of 1H, 13C and DEPT were obtained using 
Bruker 300.13, 400.13 or 600.13 MHz for 1H, and 75.5, 90.61 MHz or 
150.90 for 13C. The same spectrometers were used for the acquisition of 
1H-1H homonuclear (COSY and NOESY) and 1H-13C heteronuclear 
(HSQC and HMBC) correlations. Mass spectra (MS) and high resolution 
mass spectra (HRMS) were recorded, respectively, on a Hewlett-Packard 
1100 and Bruker MicrOTOF-Q mass spectrometers under electrospray 
ionization (ESI) conditions. 
Compounds 9,[15a] 10,[15a] 21,[19] 22,[22] and 23[22] have been previously 
described. Full analytical data for new compounds are described in the 
Supporting Information. 
(E)-2-(2-Hydroxyethyliden)-19-nor-1α,25-dihydroxyprevitamin D3 (5). 
To a stirred solution of 37 (11.5 mg, 0.013 mmol) in anhydrous THF (270 
µL) at 0 ºC and in darkness, was added dropwise TBAF (117 µL, 1 M in 
THF, 0.117 mmol). After 5 min, the ice bath was removed and the 
reaction was stirred at room temperature overnight. Next, water was 
added and the mixture was extracted with EtOAc. The resulting organic 
layer was dried over Na2SO4 and evaporated to dryness. The residue 
was purified by column chromatography on silica gel using 100% EtOAc 
to afford 5 (5.4 mg, 90% yield) as a white solid. 1H-NMR (400.13 MHz, 
acetone-d6): δ 0.75 (s, 3H, Me18), 0.99 (d, 3H, Me21, J 6.4 Hz), 1.15 (s, 
6H, Me26+Me27), 0.84-2.65 (several m), 3.11 (br s, 1H, OH), 3.65 (br s, 
1H, OH), 3.89 (br s, 1H, OH), 4.02 (br s, 1H, OH), 4.22 (m, 2H, H2’), 4.87 
(s, 2H, H1+H3), 5.37 (s, 1H, H9) and 5.72-5.87 (several m, 4H, H1’, H10, H7 
and H6) ppm; HRMS (ESI+, m/z): 467.3126 (Calcd for C28H44NaO4: 
467.3132). 
(Z)-2-(2-Hydroxyethyliden)-19-nor-1α,25-dihydroxyprevitamin D3 (6). 
A procedure analogous to that described for the synthesis of 5, starting 
from 38 (17 mg, 0.020 mmol), afforded 6 (5.3 mg, 60% yield) as a white 
solid (eluent gradient for column chromatography: 90% EtOAc/hexanes - 
2% MeOH/EtOAc). 1H-NMR (400.13 MHz, acetone-d6): δ 0.79 (s, 3H, 
Me18), 0.99 (d, 3H, Me21, J 6.5 Hz), 1.15 (s, 6H, Me26+Me27), 0.84-2.66 
(several m), 2.63 (dd, 1H, H4, J 16.1, 5.4 Hz), 3.10 (s, 1H, OH), 3.64 (t, 
1H, OH, J 5.5 Hz), 3.93 (d, 1H, OH, J 5.4 Hz), 4.02 (d, 1H, OH, J 5.4 Hz), 
4.22 (apparent t, 2H, H2’, J 5.3 Hz), 4.42 (m, 1H, H3), 4.97 (t, 1H, H1, J 
4.2 Hz), 5.38 (s, 1H, H9), 5.73-5.94 (several m, 4H, H1’, H10, H7 and H6) 
ppm; HRMS (ESI+, m/z): 467.3142 (Calcd for C28H44NaO4: 467.3132). 
(E)-1-(2-Hydroxyethyliden)-19-nor-2α,25-dihydroxyprevitamin D3 (7). 
A procedure analogous to that described for the synthesis of 5, starting 
from 39 (6 mg, 0.008 mmol), afforded 7 (3 mg, 85% yield) as a white 
solid (eluent for column chromatography: 100% EtOAc). The reaction 
was monitored by TLC (20% Et2O/hexanes, 3-4 h). 1H-NMR (600.13 MHz, 
acetone-d6): δ 0.79 (s, 3H, Me18), 0.82-2.31 (several m), 0.99 (d, 3H, 
Me21, J 6.6 Hz), 1.15 (s, 6H, Me26+Me27), 2.36 (dd, 1H, H4ax, J 17.5, 9.1 
Hz), 2.65 (dd, 1H, H4ec, J 17.1, 5.1 Hz), 3.09 (s, 1H, OH), 3.49 (s, 1H, 
OH), 3.60 (apparent t, 1H, H5, J 5.5 Hz), 3.92 (br s, 2H, OH), 4.08 (br s, 
1H, H4), 4.23 (m, H, H2’), 4.30 (m, H, H2’), 5.42 (s, 1H, H9), 5.79 (d, 1H, 
H7, J 11.8 Hz), 5.85 (t, 1H, H1’, J 6.8 Hz), 5.94 (d, 1H, H6, J 12.2 Hz), 
6.42 (s, 1H, H10) ppm; HRMS (ESI+, m/z): 467.3157 (Calcd for 
C28H44NaO4: 467.3132). 
(3R,5R)-3,5-Di[(tert-butyldimethylsilyl)oxy]-1-ethynyl-4-oxo-1-
cyclohexene (11). To a stirred solution of 10 (185 mg, 0.484 mmol) in 
anhydrous CH2Cl2 (3.2 mL) was added Dess-Martin periodinane (308 mg, 
0.726 mmol). The resulted suspension was stirred overnight at room 
temperature. The solution was then diluted with Et2O (6 mL) and a 1:1 
mixture (v/v, 6 mL) of saturated aqueous Na2S2O3 and saturated 
NaHCO3, generating a white suspension which turned clear after ten 
minutes. After extraction of the aqueous layer with Et2O, the resulting 
organic layer was dried (Na2SO4) and evaporated to dryness. The 
residue was purified by flash chromatography on silica gel 60 Å (32-63 
µm) pH 7 using 1-2% Et2O/hexanes to afford ketone 11 (144 mg, 78%) 
as a colorless thick oil. 1H-NMR (300.13 MHz, CDCl3): δ 0.08 (s, 3H, 
SiMe), 0.10 (s, 6H, SiMe2), 0.12 (s, 3H, SiMe), 0.90 (s, 9H, SiCMe3), 0.91 
(s, 9H, SiCMe3), 2.60 (ddt, 1H, H6, J 17.5, 6.5, 1.2 Hz), 2.82 (ddt, 1H, H6, 
J 17.4, 5.7, 1.4 Hz), 2.94 (s, 1H, H8), 4.55 (dd, 1H, H5, J 6.5, 5.7 Hz), 
4.78 (apparent d, 1H, H3, J 3.8 Hz) and 6.08 (m, 1H, H2) ppm; MS (ESI+, 
m/z): 419 [(M+K)+, 100%], 403 [(M+Na)+, 60%]. 
(E)- and (Z)-(3R,5R)-3,5-Di[(tert-butyldimethylsilyl)oxy]-4-
cyanomethylidene-1-ethynyl-1-cyclohexene (12). To a stirred solution 
of diethyl (cyanomethyl)phosphonate (419 mg, 2.367 mmol) in anhydrous 
THF (10 mL) at -40 ºC was added nBuLi (1.3 mL, 1.6 M in hexanes, 
2.129 mmol). The mixture was stirred for 15-20 min after which time a 
solution of 11 (450 mg, 1.183 mmol) in anhydrous THF (10 mL) was 
added dropwise. The resulting deep red solution was stirred at -40 ºC for 
additionally 1 h, after which the mixture was quenched with saturated 
NH4Cl and extracted with EtOAc. The organic layer was dried over 
Na2SO4, filtered and concentrated under vacuum. The residue was 
purified by flash chromatography on silica gel using 1-3% Et2O/hexanes 
to afford 12 (392 mg, 82%) as a white solid mixture of diastereoisomers 
E/Z in a ratio 60:40. 1H-NMR (300.13 MHz, CDCl3): (E-isomer) δ 0.09-
0.17 (several s, 12H, 4SiMe), 0.89-0.94 (several s, 18H, 2SiCMe3), 2.42 
(d, 1H, H6, J 17.9 Hz), 2.60 (m, 1H, H6), 2.89 (s, 1H, H8), 5.06 (dd, 1H, H5, 
J 3.3, 2.3 Hz), 5.20 (sa, 1H, H3), 5.46 (d, 1H, H1’, J 2.0 Hz) and 5.94 (sa, 
1H, H2) ppm; (Z-isomer) δ 0.09-0.17 (several s, 12H, 4SiMe), 0.89-0.94 
(several s, 18H, 2SiCMe3), 2.21 (ddd, 1H, H6ax, J 15.6, 9.5, 1.6 Hz), 2.66 
(dd, 1H, H6ec, J 16.6, 6.2 Hz), 2.94 (s, 1H, H8), 4.77 (m, 1H, H5), 5.12 (d, 
1H, H3, J 5.0 Hz), 5.58 (d, 1H, H1’, J 1.8 Hz) and 6.08 (dd, 1H, H2, J 4.7, 
2.2 Hz) ppm; MS (ESI+, m/z): 426 [(M+Na)+, 100%]. 
(E)- and (Z)-(3R,5R)-3,5-Di[(tert-butyldimethylsilyl)oxy]-1-ethynyl-4-
formylmethylidene-1-cyclohexene (13). To a stirred solution of 11 (50 
mg, 0.123 mmol) in anhydrous toluene (1.2 mL) at -78 ºC was added 
dropwise DIBAL-H (370 µL, 1 M in toluene, 0.370 mmol). The mixture 
was stirred at this temperature for 1 h and diluted with hexane. The 
solution was loaded directly on top of a silica gel column and eluted with 
2-3% Et2O/hexanes, to give 13 (33 mg, 65%) as a white solid (E/Z 60:40). 
1H-NMR (300.13 MHz, CDCl3): (E-isomer) δ 0.06-0.13 (several s, 12H, 
4SiMe), 0.88-0.94 (several s, 18H, 2SiCMe3), 2.47 (dd, 1H, H6, J 17.6, 
3.6 Hz), 2.63 (m, 1H, H6), 2.89 (s, 1H, H8), 5.21 (br s, 1H, H3), 5.51 
(apparent t, 1H, H5, J 3.8 Hz), 6.02 (br s, 1H, H2), 6.12 (m, 1H, H1’) and 
10.17 (d, 1H, H2’, J 7.3 Hz) ppm; (Z-isomer) δ 0.06-0.13 (several s, 12H, 
4SiMe), 0.88-0.94 (several s, 18H, 2SiCMe3), 2.27 (ddd, 1H, H6ax, J 16.8, 
9.5, 2.4 Hz), 2.68 (m, 1H, H6ec), 2.94 (s, 1H, H8), 4.81 (ddd, 1H, H5, J 9.2, 
6.4, 1.5 Hz), 5.65 (d, 1H, H3, J 5.1 Hz), 6.12 (m, 1H, H2), 6.25 (dd, 1H, H1’, 
J 7.8, 1.5 Hz) and 10.11 (d, 1H, H2’, J 7.8 Hz) ppm; MS (ESI+, m/z): 429 
[(M+Na)+, 100%]. 
(E)- and (Z)-(3R,5R)-3,5-Di[(tert-butyldimethylsilyl)oxy]-1-ethynyl-4-
(2-hydroxyethylidene)-1-cyclohexene (14). To a stirred solution of the 
    
 
 
 
 
 
aldehyde 13 (117.8 mg, 0.290 mmol) in EtOH (3.6 mL) at 0 ºC was 
added portionwise NaBH4 (11 mg, 0.290 mmol). After being stirred for 45 
min at this temperature, some drops of cold water were added and the 
mixture was extracted with EtOAc. The resulting organic layer was dried 
(Na2SO4), filtered and concentrated under vacuum. The residue was 
purified by flash chromatography on silica gel using 10% EtOAc/hexanes 
to give 14 (92 mg, 78%) as a colorless oil (E/Z 60:40). 1H-NMR (300.13 
MHz, CDCl3): (E-isomer) δ 0.07-0.12 (several s, 12H, 4SiMe), 0.87-0.94 
(several s, 18H, 2SiCMe3), 2.33 (dd, 1H, H6, J 17.3, 4.1 Hz), 2.47 (m, 1H, 
H6), 2.84 (s, 1H, H8), 4.17 (dd, 1H, H2’, J 12.9, 6.7 Hz), 4.32 (dd, 1H, H2’, 
J 13.0, 6.8 Hz), 4.91 (apparent t, 1H, H5, J 4.1 Hz), 4.97 (br s, 1H, H3), 
5.73 (apparent t, 1H, H1’, J 6.7 Hz) and 6.05 (br s, 1H, H2) ppm; (Z-
isomer) δ 0.07-0.12 (several s, 12H, 4SiMe), 0.87-0.94 (several s, 18H, 
2SiCMe3), 2.16 (m, 1H, H6), 2.55 (dd, 1H, H6, J 16.7, 5.9 Hz), 2.89 (s, 1H, 
H8), 4.26 (d, 2H, H2’, J 6.9 Hz), 4.60 (m, 1H, H5), 5.01 (d, 1H, H3, J 4.9 
Hz), 5.85 (t, 1H, H1’, J 7.1 Hz) and 6.05 (br s, 1H, H2) ppm. MS (ESI+, 
m/z): 431 [(M+Na)+, 100%]. 
(E)- and (Z)-(3R,5R)-3,5-Di[(tert-butyldimethylsilyl)oxy]-4-[2-(tert-
butyldimethylsilyl)oxyethylidene]-1-ethynyl-1-cyclohexene (15a and 
15b). To a stirred solution of 14 (123 mg, 0.301 mmol) in anhydrous 
CH2Cl2 (1.5 mL) at 0 ºC were added imidazole (27 mg, 0.391 mmol) and 
TBSCl (54 mg, 0.361 mmol). After addition, the ice bath was removed 
and the reaction was stirred for 1 h. Afterwards, water was added and the 
mixture was extracted with CH2Cl2. The resulting organic layer was 
washed with brine, dried over Na2SO4, filtered and concentrated under 
vacuum. The resulting residue was purified by flash chromatography on 
silica gel using 1% Et2O/hexanes to obtain 15 (152 mg, 97% yield) as a 
mixture of diastereoisomers. This mixture was further purified by HPLC 
chromatography (Spherisorb W, 5 µm, 250 × 20 mm, 0.05% 
iPrOH/hexanes, 4 mL min-1) to give 15a (64.6 mg) and 15b (56.3 mg), 
both colorless oils. 15a (E-isomer): 1H-NMR (400.13 MHz, CDCl3): δ 0.05 
(s, 3H, SiMe), 0.06 (s, 3H, SiMe), 0.07 (s, 3H, SiMe), 0.08 (s, 3H, SiMe), 
0.10 (s, 3H, SiMe), 0.11 (s, 3H, SiMe), 0.88 (s, 9H, SiCMe3), 0.90 (s, 9H, 
SiCMe3), 0.94 (s, 9H, SiCMe3), 2.29 (dt, 1H, H6, J 17.3, 1.6 Hz), 2.44 
(ddd, 1H, H6, J 17.3, 6.3, 2.7 Hz), 2.83 (s, 1H, H8), 4.23 (ddd, 1H, H2’, J 
13.1, 5.3, 1.4 Hz), 4.37 (ddd, 1H, H2’, J 13.1, 7.2, 1.0 Hz), 4.90 (apparent 
t, 1H, H5, J 3.5 Hz), 5.03 (br s, 1H, H3), 5.60 (ddd, 1H, H1’, J 7.1, 5.4, 1.7 
Hz) and 6.05 (br s, 1H, H2) ppm; MS (ESI+, m/z): 545 [(M+Na)+, 100%]; 
HRMS (ESI+, m/z): 545.3292 (Calcd for C28H54NaO3Si3: 545.3273). 15b 
(Z-isomer): 1H-NMR (400.13 MHz, CDCl3): δ 0.062 (s, 3H, SiMe), 0.066 
(s, 3H, SiMe), 0.069 (s, 3H, SiMe), 0.081 (s, 3H, SiMe), 0.084 (s, 3H, 
SiMe), 0.10 (s, 3H, SiMe), 0.87 (s, 9H, SiCMe3), 0.90 (s, 9H, SiCMe3), 
0.93 (s, 9H, SiCMe3), 2.15 (ddd, 1H, H6ax, J 16.5, 9.7, 2.3 Hz), 2.53 (dd, 
1H, H6ec, J 16.7, 5.9 Hz), 2.88 (s, 1H, H8), 4.29 (dd, 2H, H2’, J 6.6, 1.4 Hz), 
4.58 (ddd, 1H, H5, J 9.3, 5.9, 1.3 Hz), 4.95 (d, 1H, H3, J 5.0 Hz), 5.74 (dt, 
1H, H1’, J 6.5, 1.6 Hz) and 6.06 (dd, 1H, H2, J 4.8, 2.3 Hz) ppm; MS (ESI+, 
m/z): 545 [(M+Na)+, 100%]; HRMS (ESI+, m/z): 545.3263 (Calcd for 
C28H54NaO3Si3: 545.3273). 
(3R,4R,5R)-4,5-Di[(tert-butyldimethylsilyl)oxy]-1-ethynyl-3-hydroxy-
1-cyclohexene (16).  To a stirred solution of TMSCHN2 (1.12 mL, 2.0 M 
in hexanes, 2.250 mmol) in anhydrous THF (8 mL) at -78 ºC was added 
nBuLi (1.53 mL, 1.6 M in hexanes, 2.455 mmol). After 15 min at this 
temperature, a solution of 9 (790 mg, 2.045 mmol) in anhydrous THF (6.2 
mL) was added to this mixture and stirred at -78 ºC for additional 5 min. 
Afterwards, the reaction was further stirred gaining room temperature 
over 16 h. The reaction is then stopped by addition of water (2 mL). THF 
is then evaporated and the resulting aqueous phase is extracted with 
Et2O/H2O. The combined organic fractions were washed with brine, dried 
(Na2SO4) and concentrated to give a crude, that after purification by flash 
chromatography on silica gel (5% EtOAc/hexanes) affords a 1:1 mixture 
of isomers 10 and 16 (442 mg, 56%). The two compounds are separated 
by semi-preparative HPLC (Kromasil 250 x 20 mm, 5% EtOAc/hexanes, 
7 mL·min-1) giving 10 (217 mg, 28%) and 16 (211 mg, 27%). White solid; 
1H-NMR (300.13 MHz, CDCl3): δ 0.07 (s, 3H, SiMe), 0.08 (s, 3H, SiMe), 
0.12 (s, 3H, SiMe), 0.13 (s, 3H, SiMe), 0.88 (s, 9H, SiCMe3), 0.91 (s, 9H, 
SiCMe3), 2.03 (d, 1H, H6ax, J 17.4 Hz), 2.27 (d, 1H, OH, J 9.7 Hz), 2.50 (d, 
1H, H6ec, J 17.6 Hz), 2.85 (s, 1H, H8), 3.78 (m, 1H, H4), 3.99 (m, 1H, H5), 
4.28 (d, 1H, H3, J 7.9 Hz) and 6.04 (s, 1H, H2) ppm; MS (ESI+, m/z): 405 
[(M+Na)+, 100%]. 
(4S,5R)-4,5-Di[(tert-butyldimethylsilyl)oxy]-1-ethynyl-3-oxo-1-
cyclohexene (17). To a stirred solution of 16 (103 mg, 0.269 mmol) in 
anhydrous CH2Cl2 (2.7 mL) was added MnO2 (234 mg, 2.695 mmol). The 
resulting suspension was stirred at room temperature overnight and 
filtered afterwards over Celite. The filtrate was concentrated under 
vacuum and the resulting residue was purified by flash chromatography 
with a 1.5% EtOAc/hexanes to afford 17 (88 mg, 86% yield) as a white 
solid. 1H-NMR (300.13 MHz, CDCl3): δ 0.079 (s, 3H, SiMe), 0.082 (s, 6H, 
2SiMe), 0.10 (s, 3H, SiMe), 0.87 (s, 9H, SiCMe3), 0.91 (s, 9H, SiCMe3), 
2.44 (ddd, 1H, H6, J 18.0, 5.8, 1.7 Hz), 2.81 (ddd, 1H, H6, J 18.0, 4.0, 1.5 
Hz), 3.51 (s, 1H, H8), 3.90 (d, 1H, H4, J 7.2 Hz), 4.05 (ddd, 1H, H5, J 7.1, 
5.9, 4.1 Hz) and 6.22 (s, 1H, H2) ppm; MS (ESI+, m/z): 381 [(M+H)+, 
100%], 403 [(M+Na)+, 75%]. 
(E)-(4R,5R)-4,5-Di[(tert-butyldimethylsilyl)oxy]-3-cyanomethylidene-
1-ethynyl-1-cyclohexene (18). A procedure analogous to that described 
for the synthesis of 12, starting from 17 (85 mg, 0.224 mmol), afforded 18 
(80 mg, 89% yield) after 2.5 h as a yellow solid and a single 
diastereoisomer (eluent for column chromatography: 1.5% 
EtOAc/hexanes). 1H-NMR (300.13 MHz, CDCl3): δ 0.06 (s, 3H, SiMe), 
0.07 (s, 3H, SiMe), 0.08 (s, 3H, SiMe), 0.12 (s, 3H, SiMe), 0.87 (s, 9H, 
SiCMe3), 0.90 (s, 9H, SiCMe3), 2.31 (dd, 1H, H6, J 18.0, 5.4 Hz), 2.69 (dd, 
1H, H6, J 18.1, 3.0 Hz), 3.26 (s, 1H, H8), 3.85 (m, 1H, H5), 4.03 (dd, 1H, 
H4, J 6.7, 0.9 Hz), 5.29 (s, 1H, H1’) and 6.91 (s, 1H, H2) ppm; 13C-NMR 
(75.5 MHz, CDCl3): δ -4.7 (SiMe), -4.5 (SiMe), -4.1 (2SiMe), 18.1 (SiC), 
18.2 (SiC), 26.0 (2SiCMe3), 37.0 (C6), 70.2 (C5), 73.4 (C4), 82.7 (C8), 
83.8 (C7), 95.6 (C1’), 116.5 (CN), 126.5 (C1), 129.7 (C2) and 157.1 
(C3) ppm. 
(E)-(4R,5R)-4,5-Di[(tert-butyldimethylsilyl)oxy]-1-ethynyl-3-
formylmethylidene-1-cyclohexene (19). A procedure analogous to that 
described for the synthesis of 13, starting from 18 (93 mg, 0.231 mmol), 
afforded 19 (80 mg, 85% yield) as a yellow oil (eluent for column 
chromatography: 5-10% EtOAc/hexanes). 1H-NMR (300.13 MHz, CDCl3): 
δ 0.04 (s, 3H, SiMe), 0.06 (s, 3H, SiMe), 0.07 (s, 3H, SiMe), 0.11 (s, 3H, 
SiMe), 0.84 (s, 9H, SiCMe3), 0.88 (s, 9H, SiCMe3), 2.29 (dd, 1H, H6, J 
18.0, 3.8 Hz), 2.75 (apparent dt, 1H, H6, J 18.1, 3.0 Hz), 3.25 (s, 1H, H8), 
3.93 (apparent dt, 1H, H5, J 5.5, 3.8 Hz), 4.02 (d, 1H, H4, J 5.5 Hz), 5.87 
(d, 1H, H1’, J 8.0 Hz), 7.35 (s, 1H, H2) and 10.18 (d, 1H, H2’, J 8.0 Hz) 
ppm; MS (ESI+, m/z): 407 [(M+H)+, 45%]; HRMS (ESI+, m/z): 429.2256 
(Calcd for C22H38NaO3Si2: 429.2252). 
(E)-(4R,5R)-4,5-Di[(tert-butyldimethylsilyl)oxy]-1-ethynyl-3-(2-
hydroxyethylidene)-1-cyclohexene (20). A procedure analogous to that 
described for the synthesis of 14, starting from 19 (65 mg, 0.160 mmol), 
afforded 20 (43 mg, 65% yield) as a yellow thick oil (eluent for column 
chromatography: 10% EtOAc/hexanes). 1H-NMR (300.13 MHz, CDCl3): δ 
0.04 (s, 3H, SiMe), 0.05 (s, 3H, SiMe), 0.06 (s, 3H, SiMe), 0.10 (s, 3H, 
SiMe), 0.85 (s, 9H, SiCMe3), 0.87 (s, 9H, SiCMe3), 2.16 (dd, 1H, H6, J 
17.7, 3.2 Hz), 2.67 (dt, 1H, H6, J 17.7, 2.8 Hz), 3.03 (s, 1H, H8), 3.86 
(apparent dt, 1H, H5, J 5.3, 3.6 Hz), 3.92 (d, 1H, H4, J 5.3 Hz), 4.33 (d, 
2H, H2’, J 6.9 Hz), 5.65 (t, 1H, H1’, J 6.9 Hz) and 6.70 (s, 1H, H2) ppm; 
MS (ESI+, m/z): 447 [(M+K)+, 100%]; HRMS (ESI+, m/z): 431.2360 (Calcd 
for C22H40NaO3Si2: 431.2408). 
    
 
 
 
 
 
(3R,4S,5R)-3-[(tert-Butyldimethylsilyl)oxy]-1-formyl-4,5-(2,3-
dimethoxybutan-2,3-dioxy)-1-cyclohexene (24). A procedure 
analogous to that described for the synthesis of 11, starting from 23 (170 
mg, 0.438 mmol), afforded 24 (159 mg, 94% yield) after 2 h as a white 
solid (eluent for column chromatography: 10% EtOAc/hexanes). 1H-NMR 
(300.13 MHz, CDCl3): δ 0.11 (s, 3H, SiMe), 0.13 (s, 3H, SiMe), 0.89 (s, 
9H, SiCMe3), 1.27 (s, 3H, Me), 1.29 (s, 3H, Me), 2.07 (ddd, 1H, H6ax, J 
17.0, 10.3, 1.9 Hz), 2.73 (dd, 1H, H6ec, J 17.5, 6.0 Hz), 3.21 (s, 3H, OMe), 
3.24 (s, 3H, OMe), 3.52 (dd, 1H, H4, J 10.8, 3.8 Hz), 4.08 (apparent td, 
1H, H5, J 10.6, 6.0 Hz), 4.44 (apparent t, 1H, H3, J 4.4 Hz), 6.57 (dd, 1H, 
H2, J 4.8, 2.2 Hz) and 9.51 (s, 1H, H7) ppm; MS (ESI+, m/z): 355 [(M-
OCH3)+, 100%], 409 [(M+Na)+, 65%]. 
(3R,4S,5R)-3-[(tert-Butyldimethylsilyl)oxy]-1-ethynyl-4,5-(2,3-
dimethoxybutan-2,3-dioxy)-1-cyclohexene (25). To a stirred solution of 
TMSCHN2 (346 µL, 2.0 M in hexanes, 0.692 mmol) in anhydrous THF 
(2.5 mL) at -78 ºC was added nBuLi (472 µL, 1.6 M in hexanes, 0.755 
mmol). After 15 min at this temperature, a solution of 24 (243 mg, 
0.629 mmol) in anhydrous THF (2.5 mL) was added to this mixture and 
stirred at -78 ºC for additional 5 min. Afterwards, the cooling bath was 
removed and the reaction was let to reach room temperature for over 1 h. 
Then, the reaction was poured into H2O/Et2O and the aqueous layer 
extracted with Et2O. The combined organic fractions were washed with 
brine, dried (Na2SO4) and concentrated, and the residue was purified by 
flash chromatography on silica gel (5% EtOAc/hexanes) to afford 25 (156 
mg, 65%) as a white solid. 1H-NMR (300.13 MHz, CDCl3): δ 0.08 (s, 3H, 
SiMe), 0.11 (s, 3H, SiMe), 0.89 (s, 9H, SiCMe3), 1.28 (s, 3H, Me), 1.29 (s, 
3H, Me), 2.26 (ddd, 1H, H6ax, J 17.0, 10.3, 2.4 Hz), 2.49 (dd, 1H, H6ec, J 
17.1, 6.1 Hz), 2.87 (s, 1H, H8), 3.23 (s, 3H, OMe), 3.25 (s, 3H, OMe), 
3.48 (dd, 1H, H4, J 10.8, 3.8 Hz), 4.14 (apparent td, 1H, H5, J 10.5, 6.2 
Hz), 4.22 (apparent t, 1H, H3, J 4.6 Hz) and 6.07 (dd, 1H, H2, J 5.1, 2.1 
Hz) ppm; MS (ESI+, m/z): 351 [(M-OCH3)+, 100%], 405 [(M+Na)+, 80%]. 
(3R,4S,5R)-1-Ethynyl-3-hydroxy-4,5-(2,3-dimethoxybutan-2,3-dioxy)-
1-cyclohexene (26). To a stirred solution of silyl ether 25 (120 mg, 0.314 
mmol) in anhydrous THF (6 mL) at 0 ºC and in darkness, was added 
dropwise TBAF (785 µL, 1 M in THF, 0.785 mmol). After 10 min at this 
temperature, the ice bath was removed and the reaction was stirred at 
room temperature until complete consumption of the starting material 
(monitored by TLC 10% EtOAc/hexanes, 2-3 h). The reaction was 
stopped by addition of water followed by extraction with EtOAc. The 
resulting organic layer was washed with brine, dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography on silica 
gel (25% EtOAc/hexanes) to afford 26 (80 mg, 95%) as a white semisolid. 
1H-NMR (300.13 MHz, CDCl3): δ 1.29 (s, 3H, Me), 1.33 (s, 3H, Me), 2.30 
(ddd, 1H, H6ax, J 17.0, 10.4, 2.6 Hz), 2.49 (dd, 1H, H6ec, J 17.1, 5.9 Hz), 
2.77 (br s, 1H, OH), 2.91 (s, 1H, H8), 3.25 (s, 3H, OMe), 3.26 (s, 3H, 
OMe), 3.60 (dd, 1H, H4, J 10.8, 4.2 Hz), 4.12 (apparent td, 1H, H5, J 10.6, 
6.0 Hz), 4.28 (apparent t, 1H, H3, J 4.7 Hz) and 6.18 (dd, 1H, H2, J 5.4, 
2.5 Hz) ppm; MS (ESI+, m/z): 291 [(M+Na)+, 100%]. 
(4S,5R)-1-Ethynyl-4,5-(2,3-dimethoxybutan-2,3-dioxy)-3-oxo-1-
cyclohexene (27). A procedure analogous to that described for the 
synthesis of 11, starting from 26 (75 mg, 0.280 mmol), afforded 27 (68 
mg, 91% yield) after 2 h as a white solid (eluent for column 
chromatography: 20% EtOAc/hexanes). 1H-NMR (300.13 MHz, CDCl3): δ 
1.32 (s, 3H, Me), 1.41 (s, 3H, Me), 2.72 (m, 2H, H6), 3.25 (s, 3H, OMe), 
3.30 (s, 3H, OMe), 3.59 (s, 1H, H8), 4.11 (m, 1H, H5), 4.27 (d, 1H, H4, J 
11.5 Hz) and 6.29 (d, 1H, H2, J 1.3 Hz) ppm; MS (ESI+, m/z): 289 
[(M+Na)+, 100%]. 
(E)-(4R,5R)-3-Cyanomethylidene-1-ethynyl-4,5-(2,3-dimethoxybutan-
2,3-dioxy)-1-cyclohexene (28). A procedure analogous to that 
described for the synthesis of 12, starting from 27 (60 mg, 0.225 mmol), 
afforded 28 (52 mg, 80% yield) after 4 h as a yellow solid and a single 
diastereoisomer (eluent for column chromatography: 10% 
EtOAc/hexanes). 1H-NMR (400.13 MHz, CDCl3): δ 1.33 (s, 3H, Me), 1.38 
(s, 3H, Me), 2.53 (ddd, 1H, H6ax, J 17.8, 10.3, 1.9 Hz), 2.61 (dd, 1H, H6ec, 
J 17.6, 6.0 Hz), 3.26 (s, 3H, OMe), 3.27 (s, 3H, OMe), 3.31 (s, 1H, H8), 
3.85 (apparent td, 1H, H5, J 10.5, 6.0 Hz), 4.30 (dd, 1H, H4, J 10.8, 2.2 
Hz), 5.57 (s, 1H, H15) and 6.91 (d, 1H, H2, J 2.4 Hz) ppm; MS (ESI+, m/z): 
312 [(M+Na)+, 100%]. 
(E)-(4R,5R)-1-Ethynyl-3-formylmethylidene-4,5-(2,3-dimethoxybutan-
2,3-dioxy)-1-cyclohexene (29). A procedure analogous to that 
described for the synthesis of 13, starting from 28 (169 mg, 0.586 mmol), 
afforded 29 (151 mg, 88% yield) as a yellow solid (eluent for column 
chromatography: 20% EtOAc/hexanes). 1H-NMR (300.13 MHz, CDCl3): δ 
1.33 (s, 3H, Me), 1.38 (s, 3H, Me), 2.52 (ddd, 1H, H6ax, J 17.8, 10.5, 2.5 
Hz), 2.63 (dd, 1H, H6ec, J 17.6, 6.0 Hz), 3.26 (s, 3H, OMe), 3.27 (s, 3H, 
OMe), 3.29 (s, 1H, H8), 3.92 (apparent td, 1H, H5, J 10.6, 6.0 Hz), 4.33 
(dd, 1H, H4, J 10.7, 2.1 Hz), 6.28 (d, 1H, H15, J 7.6 Hz), 7.39 (d, 1H, H2, J 
2.1 Hz) and 10.14 (d, 1H, CHO, J 7.6 Hz) ppm; MS (ESI+, m/z): 315 
[(M+Na)+, 100%]. 
(E)-(4R,5R)-1-Ethynyl-3-(2-hydroxyethylidene)-4,5-(2,3-
dimethoxybutan-2,3-dioxy)-1-cyclohexene (30). A procedure 
analogous to that described for the synthesis of 14, starting from 29 (85 
mg, 0.291 mmol), afforded 30 (64 mg, 75% yield) as a yellowish 
semisolid of low stability (eluent for column chromatography: 30% 
EtOAc/hexanes). 1H-NMR (400.13 MHz, CDCl3): δ 1.33 (s, 3H, Me), 1.39 
(s, 3H, Me), 2.49 (m, 2H, H6), 3.08 (s, 1H, H8), 3.26 (s, 3H, OMe), 3.29 (s, 
3H, OMe), 3.81 (ddd, 1H, H5, J 10.6, 9.5, 7.0 Hz), 4.20 (d, 1H, H4, J 10.6 
Hz), 4.30 (dd, 1H, H16, J 13.5, 6.0 Hz), 4.38 (dd, 1H, H16, J 12.9, 7.6 Hz), 
6.01 (apparent t, 1H, H15, J 6.5 Hz) and 6.74 (s, 1H, H2) ppm. 
(E)-(4R,5R)-3-[2-(tert-Butyldimethylsilyl)oxyethylidene]-1-ethynyl-
4,5-(2,3-dimethoxybutan-2,3-dioxy)-1-cyclohexene (31). A procedure 
analogous to that described for the synthesis of 15, starting from 30 (113 
mg, 0.384 mmol), afforded 31 (126 mg, 80% yield) as a thick colorless oil 
(eluent for column chromatography: 5% EtOAc/hexanes). 1H-NMR 
(300.13 MHz, CDCl3): δ 0.077 (s, 3H, SiMe), 0.080 (s, 3H, SiMe), 0.91 (s, 
9H, SiCMe3), 1.32 (s, 3H, Me), 1.38 (s, 3H, Me), 2.46 (apparent d, 2H, H6, 
J 7.9 Hz), 3.04 (s, 1H, H8), 3.25 (s, 3H, OMe), 3.28 (s, 3H, OMe), 3.79 (m, 
1H, H5), 4.17 (dd, 1H, H4, J 10.6, 2.1 Hz), 4.27 (ddd, 1H, H16, J 13.8, 5.2, 
2.2 Hz), 4.45 (ddd, 1H, H16, J 13.8, 7.7, 1.6 Hz), 5.91 (apparent td, 1H, 
H15, J 6.7, 1.2 Hz) and 6.73 (s, 1H, H2) ppm; HRMS (ESI+, m/z): 
431.2233 (Calcd for C22H36NaO5Si: 431.2224). 
General procedure for the synthesis of 33-36. 
To a stirred solution of vinyl triflate 32 (27 mg, 0.056 mmol) and the 
corresponding A-ring precursor 15a, 15b, 20 or 31 (0.071 mmol) in 
deoxygenated anhydrous DMF (490 µL), were added CuI (1.2 mg, 
0.006 mmol), (Ph3P)2Pd(OAc)2 (1.4 mg, 0.002 mmol) and deoxygenated 
anhydrous Et2NH (490 µL). After 2 h stirring at room temperature, water 
was added and the mixture was extracted with Et2O. The resulting 
organic layer was dried over Na2SO4, filtered and concentrated under 
vacuum to give a residue that was purified by flash chromatography on 
silica gel (eluents: 1% Et2O/hexanes for 33-34; 10% Et2O/hexanes for 35; 
and 2% EtOAc/hexanes for 36).  
(E)-(1R,3R)-1,3-Di[(tert-butyldimethylsilyl)oxy]-2-[2-(tert-
butyldimethylsilyl)oxyethylidene]-6,7-dehydro-25-trimethylsilyloxy-
19-nor-previtamin D3 (33). Colorless oil, 70% yield; 1H-NMR (300.13 
MHz, CDCl3): δ 0.05 (s, 3H, SiMe), 0.06 (s, 3H, SiMe), 0.07 (s, 3H, SiMe), 
0.08 (s, 3H, SiMe), 0.10 (s, 3H, SiMe), 0.107 (s, 3H, SiMe), 0.113 (s, 9H, 
    
 
 
 
 
 
TMS), 0.70 (s, 3H, Me18), 0.88 (s, 9H, SiCMe3), 0.90 (s, 9H, SiCMe3), 
0.94 (s, 9H, SiCMe3), 1.21 (s, 6H, Me26+Me27), 0.88-2.47 (several m), 
4.23 (ddd, 1H, H2’, J 13.1, 5.2, 1.3 Hz), 4.39 (ddd, 1H, H2’, J 13.1, 7.2, 0.9 
Hz), 4.88 (t, 1H, H3, J 3.6 Hz), 5.01 (s, 1H, H1), 5.58 (m, 1H, H1’), 5.89 (s, 
1H, H10) and 5.96 (d, 1H, H9, J 3.0 Hz) ppm; MS (ESI+, m/z): 725 [(M-
OTBS)+, 100%]; HRMS (ESI+, m/z): 879.5942 (Calcd for C49H92NaO4Si4: 
879.5965). 
(Z)-(1R,3R)-1,3-Di[(tert-butyldimethylsilyl)oxy]-2-[2-(tert-
butyldimethylsilyl)oxyethylidene]-6,7-dehydro-25-trimethylsilyloxy-
19-nor-previtamin D3 (34). Colorless oil, 90% yield; 1H-NMR (300.13 
MHz, CDCl3): δ 0.06 (s, 9H, 3SiMe), 0.08 (s, 6H, 2SiMe), 0.09 (s, 3H, 
SiMe), 0.11 (s, 9H, TMS), 0.70 (s, 3H, Me18), 0.86 (s, 9H, SiCMe3), 0.90 
(s, 9H, SiCMe3), 0.93 (s, 9H, SiCMe3), 0.95 (d, 3H, Me21, J 6.6 Hz), 1.21 
(s, 6H, Me26+Me27), 1.22-2.26 (several m), 2.51 (dd, 1H, H4, J 16.7, 6.0 
Hz), 4.29 (dd, 2H, H2’, J 6.6, 1.4 Hz), 4.59 (dd, 1H, H3, J 8.7, 6.9 Hz), 
4.94 (d, 1H, H1, J 5.3 Hz), 5.72 (dd, 1H, H1’, J 6.6, 4.9 Hz), 5.89 (dd, 1H, 
H10, J 5.0, 2.3 Hz) and 5.99 (d, 1H, H9, J 3.0 Hz) ppm; MS (ESI+, m/z): 
725 [(M-OTBS)+, 100%]; HRMS (ESI+, m/z): 879.5920 (Calcd for 
C49H92NaO4Si4: 879.5965). 
(E)-(2R,3R)-2,3-Di[(tert-butyldimethylsilyl)oxy]-6,7-dehydro-1-(2-
hydroxyethylidene)-25-trimethylsilyloxy-19-nor-previtamin D3 (35). 
Yellow thick oil, 65% yield; 1H-NMR (400.13 MHz, CDCl3): δ 0.04 (s, 3H, 
SiMe), 0.05 (s, 3H, SiMe), 0.06 (s, 3H, SiMe), 0.10 (s, 3H, SiMe), 0.11 (s, 
9H, TMS), 0.72 (s, 3H, Me18), 0.85 (s, 9H, SiCMe3), 0.88 (s, 9H, SiCMe3), 
0.96 (d, 3H, Me21, 3JHH 6.5 Hz), 0.98-2.30 (several m), 1.21 (s, 6H, 
Me26+Me27), 2.16 (dd, 1H, H4, J 17.3, 3.6 Hz), 2.67 (d, 1H, H4, J 16.8 Hz), 
3.85 (m, 1H, H3), 3.91 (d, 1H, H2, J 5.4 Hz), 4.32 (m, 2H, H2’), 5.61 (t, 1H, 
H1’, J 7.0 Hz), 6.01 (d, 1H, H9, J 3.0 Hz) and 6.55 (s, 1H, H10) ppm; MS 
(APCI, m/z): 725 [(M - OH)+, 100%]. 
(E)-(2R,3R)-1-[2-(tert-Butyldimethylsilyl)oxyethylidene]-6,7-dehydro-
2,3-(2,3-dimethoxybutan-2,3-dioxy)-25-trimethylsilyloxy-19-nor-
previtamin D3 (36). Colorless thick oil, 60% yield; 1H-NMR (600.13 MHz, 
acetone-d6): δ 0.097 (s, 3H, SiMe), 0.101 (s, 12H, SiMe+TMS), 0.73 (s, 
3H, Me18), 0.92 (s, 9H, SiCMe3), 1.00 (d, 3H, Me21, J 6.6 Hz), 1.220, 
1.222 (2s, 6H, Me26 and Me27), 1.26 (s, 3H, Me), 1.32 (s, 3H, Me), 0.91-
2.38 (several m), 2.41 (dd, 1H, H4, J 16.9, 5.8 Hz), 3.21 (s, 3H, OMe), 
3.23 (s, 3H, OMe), 3.70 (apparent td, 1H, H3, J 10.5, 5.9 Hz), 4.08 (d, 1H, 
H2, J 10.7 Hz), 4.38 (ddd, 1H, H2’, J 13.8, 6.1, 1.6 Hz), 4.47 (ddd, 1H, H2’, 
J 13.8, 6.9, 1.7 Hz), 5.82 (apparent t, 1H, H2’, J 6.4 Hz), 5.97 (apparent q, 
1H, H9, J 3.6 Hz) and 6.64 (d, 1H, H2, J 1.8 Hz) ppm. 
General procedure for the synthesis of 37-40. 
A round bottom flask containing Lindlar catalyst (30 mg), was exposed to 
a positive pressure of hydrogen gas (balloon). Then, a solution of the 
corresponding dienyne 33-36 (0.024 mmol) in hexanes (11 mL) and 
quinolone (30 µL 0.5% v/v in hexanes, 0.001 mmol) were added. The 
reaction was stirred vigorously during 4 h after which was filtered on 
Celite, whasing with a mixture of hexanes/Et2O. The filtrate was 
concentrated and the crude was purified by flash chromatography on 
silica gel (eluents: 1% Et2O/hexanes for 37-38; 15% Et2O/hexanes for 39; 
and 4% Et2O/hexanes for 40). 
(E)-(1R,3R)-1,3-Di[(tert-butyldimethylsilyl)oxy]-2-[2-(tert-
butyldimethylsilyl)oxyethylidene]-25-trimethylsilyloxy-19-nor-
previtamin D3 (37). Colorless oil, 60% yield; 1H-NMR (300.13 MHz, 
CDCl3): δ 0.04 (s, 3H, SiMe), 0.06 (s, 6H, 2SiMe), 0.07 (s, 3H, SiMe), 
0.10 (s, 3H, SiMe), 0.105 (s, 3H, SiMe), 0.113 (s, 3H, TMS), 0.71 (s, 3H, 
Me18), 0.88 (s, 9H, SiCMe3), 0.90 (s, 9H, SiCMe3), 0.95 (s, 9H, SiCMe3), 
1.21 (s, 6H, Me26+Me27), 0.87-2.42 (several m), 2.47 (dd, 1H, H4, J 17.2, 
3.9 Hz), 4.26 (dd, 1H, H2’, J 12.2, 5.2 Hz), 4.45 (dd, 1H, H2’, J 12.6, 7.2), 
4.86 (t, 1H, H3, J 3.9 Hz), 4.96 (s, 1H, H1), 5.42 (s, 1H, H9), 5.54 (t, 1H, 
H1’, J 5.3 Hz), 5.62 (s, 1H, H10), 5.71 (d, 1H, H7, J 11.9 Hz) and 5.83 (d, 
1H, H6, J 12.6 Hz) ppm; MS (APCI+, m/z): 727 [(M-OTBDMS)+, 100%]; 
HRMS (ESI+, m/z): 881.6107 (Calcd for C49H94NaO4Si4: 881.6121). 
(Z)-(1R,3R)-1,3-Di[(tert-butyldimethylsilyl)oxy]-2-[2-(tert-
butyldimethylsilyl)oxyethylidene]-25-trimethylsilyloxy-19-nor-
previtamin D3 (38). Colorless oil, 90% yield; 1H-NMR (400.13 MHz, 
CDCl3): δ 0.06 (s, 6H, 2SiMe), 0.07 (s, 6H, 2SiMe), 0.08 (s, 3H, SiMe), 
0.09 (s, 3H, SiMe), 0.12 (s, 3H, TMS), 0.74 (s, 3H, Me18), 0.87 (s, 9H, 
SiCMe3), 0.90 (s, 9H, SiCMe3), 0.93 (s, 9H, SiCMe3), 1.21 (s, 6H, 
Me26+Me27), 0.87-2.29 (several m), 2.53 (dd, 1H, H4, J 16.3, 5.6 Hz), 
4.31 (s, 2H, H2’), 4.53 (dd, 1H, H3, J 8.2, 6.1 Hz), 4.94 (d, 1H, H1, J 4.7 
Hz), 5.41 (s, 1H, H9), 5.61 (d, 1H, H10, J 3.4 Hz), 5.71 (m, 2H, H1’+H7) 
and 5.83 (d, 1H, H6, J 12.2 Hz) ppm; MS (APCI+, m/z): 727 [(M-
OTBDMS)+, 100%]; HRMS (ESI+, m/z): 881.6099 (Calcd for 
C49H94NaO4Si4: 881.6121). 
(E)-(2R,3R)-2,3-Di[(tert-butyldimethylsilyl)oxy]-1-(2-
hydroxyethylidene)-25-trimethylsilyloxy-19-nor-previtamin D3 (39). 
Yellow oil, 70% yield; 1H-NMR (300.13 MHz, CDCl3): δ 0.03 (s, 3H, SiMe), 
0.05 (s, 6H, 2SiMe), 0.08 (s, 3H, SiMe), 0.11 (s, 9H, TMS), 0.73 (s, 3H, 
Me18), 0.85 (s, 9H, SiCMe3), 0.90 (s, 9H, SiCMe3), 0.81-2.78 (several m), 
0.97 (d, 3H, Me21, J 6.5 Hz), 1.21 (s, 6H, Me26+Me27), 3.83 (m, 1H, H3), 
3.93 (d, 1H, H2, J 5.7 Hz), 4.31 (m, 2H, H2’), 5.44 (s, 1H, H9), 5.62 (t, 1H, 
H1’, J 7.0 Hz), 5.78 (d, 1H, H7, J 12.0 Hz), 5.88 (d, 1H, H6, J 12.2 Hz) and 
6.34 (s, 1H, H10) ppm. 
(E)-(2R,3R)-1-[2-(tert-Butyldimethylsilyl)oxyethylidene]-2,3-(2,3-
dimethoxybutan-2,3-dioxy)-25-trimethylsilyloxy-19-nor-previtamin 
D3 (40). Yellow oil, 75% yield; 1H-NMR (600.13 MHz, acetone-d6): δ 
0.091 (s, 3H, SiMe), 0.093 (s, 3H, SiMe), 0.10 (s, 9H, TMS), 0.79 (s, 3H, 
Me18), 0.91 (s, 9H, SiCMe3), 1.00 (d, 3H, Me21, J 6.6 Hz), 1.215, 1.217 
(2s, 6H, Me26 and Me27), 1.25 (s, 3H, Me), 1.31 (s, 3H, Me), 0.86-2.42 
(several m), 2.55 (dd, 1H, H4, J 16.8, 5.4 Hz), 3.18 (s, 3H, OMe), 3.24 (s, 
3H, OMe), 3.62 (apparent td, 1H, H3, J 10.6, 5.4 Hz), 4.09 (dd, 1H, H2, J 
10.4, 1.6 Hz), 4.37 (ddd, 1H, H2’, J 13.5, 6.1, 1.9 Hz), 4.47 (ddd, 1H, H2’, 
J 13.4, 7.0, 1.7 Hz), 5.46 (br s, 1H, H9), 5.77 (apparent t, 1H, H2’, J 5.6 
Hz), 5.84 (d, 1H, H7, J 11.9 Hz), 5.95 (d, 1H, H6, J 12.2 Hz) and 6.45 (s, 
1H, H2) ppm. 
In vitro Biological Evaluation 
Affinity for VDR. The affinity of 1α,25-(OH)2-D3 and its analogues to the 
vitamin D receptor was evaluated by their ability to compete with 
[3H]1α,25-(OH)2-D3 for binding to high speed supernatant from intestinal 
mucosa homogenates obtained from normal pigs as described 
previously.[23] The relative affinity of the analogues was calculated from 
their concentration needed to displace 50% of [3H]1α,25-(OH)2-D3 from 
its receptor compared with the activity of 1α,25-(OH)2-D3 (assigned a 
100% value). 
Affinity for DBP. Binding of vitamin D metabolites and analogues to 
hDBP was performed at 4 °C as described previously.[24] [3H]1α,25-
(OH)2-D3 and 1α,25-(OH)2-D3 or its analogues were incubated with hDBP 
(0.18 µM) in a final volume of 1 ml (0.01 M Tris-HCl buffer and 0.154 M 
NaCl, pH 7.4) for 3 h at 4 °C. Phase separation was then obtained by the 
addition of 0.5 ml of cold dextran-coated charcoal. 
Cell proliferation assays. As a measure of cell proliferation, [3H]-
thymidine incorporation of breast cancer MCF-7 cells (ATCC) was 
    
 
 
 
 
 
determined after a 72 h incubation period with various concentrations of 
1α,25-(OH)2-D3, analogues or vehicle as described previously.[23] 
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